Abstract

    Open Access Research Article Article ID: APT-5-125

    First case series of clozapine induced hypogammaglobulinaemia in England

    S Elkhalifa*, T Garcez, S Drinkwater, T Tan, P Vijayadurai, A Anantharachagan, A Herwadkar, H Alachkar and J Darroch

    Evidence is emerging that clozapine can adversely affect immunoglobulin levels. We present a case series of 17 clozapine-treated patients referred to clinical immunology centres in the north west of England with otherwise-unexplained hypogammaglobulinaemia. This adds to existing evidence and suggests that clozapine can cause clinically significant antibody deficiency that will sometimes require specialist intervention. We speculate that this putative drug toxicity could be mediated via interaction with PI3K (phosphatidylinositol-3-kinase) signalling pathways involved in the development and homeostasis of B cells. It may be advisable to monitor immunoglobulin levels in patients being treated with clozapine.

    Keywords:

    Published on: Mar 18, 2021 Pages: 15-18

    Full Text PDF Full Text HTML DOI: 10.17352/apt.000025
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Indexing/Archiving

    Pinterest on APT